



Neutralizing Antibody Response against SARS-CoV-2

Guest Editors:

Dr. Lalit Batra

Regional Biocontainment
Laboratory (RBL), Center for
Predictive Medicine, University of
Louisville, Louisville, KY 40292,
USA

Dr. Divyasha Saxena

Center for Predictive Medicine
(CPM), Clinical Translational
Research Building (CTRB), 505
South Hancock Street, Rm#626A,
Louisville, KY 40222, USA

Deadline for manuscript
submissions:

closed (31 August 2023)

Message from the Guest Editors

We look forward to your contributions, that include the virus neutralization data (live virus or surrogate assays) on sera samples from healthy/immune-compromised individuals with a background of vaccination against SARS-CoV-2, natural infection, or both.

For your convenience, please find *Guest Editors'* Research Interests here:

Dr. Lalit Batra: Infection and Immunity, Immunotherapy, Check-Point Inhibitors and Stimulators, T cell response against SARS-CoV-2, Viral Immunity, Translational Research, Clinical Trials, Bacterial and Viral Vaccines, Immune mechanism behind antivirals, host-pathogen immunology

Dr. Divyasha Saxena: vaccination against SARS-CoV-2; antiviral research; host–pathogen interaction

How we can have cooperation in the near future.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPLus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com